Tema Etfs LLC Acquires New Position in Genmab A/S (NASDAQ:GMAB)

Tema Etfs LLC acquired a new stake in Genmab A/S (NASDAQ:GMAB) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 58,935 shares of the company’s stock, valued at approximately $1,230,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after purchasing an additional 827 shares during the period. EverSource Wealth Advisors LLC lifted its position in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC lifted its position in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares during the period. Grandfield & Dodd LLC lifted its position in Genmab A/S by 4.2% in the fourth quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company’s stock valued at $704,000 after purchasing an additional 1,370 shares during the period. Finally, Blue Trust Inc. lifted its position in Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after purchasing an additional 1,442 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $19.88 on Friday. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.06. The company has a market capitalization of $12.75 billion, a P/E ratio of 11.43, a P/E/G ratio of 2.65 and a beta of 1.04. The business has a 50 day moving average price of $19.74 and a 200 day moving average price of $20.75.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on GMAB shares. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Sanford C. Bernstein downgraded shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. HC Wainwright reiterated a “buy” rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, Truist Financial reduced their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.